{
  "id": "clinical#risk_safety_b283a81d",
  "content": "cases, suggesting underlying vulnerability in some patients; how-\never, genetic findings based on neurotransmitter receptor polymor-\nphisms have not been replicated consistently.\nNearly all dopamine antagonists have been associated with neuro-\nleptic malignant syndrome, although high-potency antipsychotics pose\na greater risk compared with low-potency agents and newer atypical an-\ntipsychotics. Partial or milder forms may be associated with newer anti-\npsychotics, but neuroleptic malignant syndrome varies in severity even\nwith older drugs. Dopamine antagonists used in medical settings (e.g.,\nmetoclopramide, prochlorperazine) have also been implicated. Paren-\nteral administration routes, rapid titration rates, and higher total drug\ndosages have been associated with increased risk; however, neuroleptic\nmalignant syndrome usually occurs within the therapeutic dosage\nrange of antipsychotics.\nDifferential Diagnosis\nNeuroleptic malignant syndrome must be distinguished from other\nserious neurological or medical conditions, including central ner-\nvous system infections, inflammatory or autoimmune conditions,\nstatus epilepticus, subcortical structural lesions, and systemic condi-\ntions (e.g., pheochromocytoma, thyrotoxicosis, tetanus, heat stroke).\nMedication-Induced Movement Disorders 349\nNeuroleptic malignant syndrome also must be distinguished from\nsimilar syndromes resulting from the use of other substances or medi-\ncations, such as serotonin syndrome; parkinsonian hyperthermia syn-\ndrome following abrupt discontinuation of dopamine agonists; alcohol",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety cases, suggesting underlying vulnerability in some patients; how-\never, genetic findings based on neurotransmitter receptor polymor-\nphisms have not been replicated consistently.\nNearly all dopamine antagonists have been associated with neuro-\nleptic malignant syndrome, although high-potency antipsychotics pose\na greater risk compared with low-potency agents and newer atypical an-\ntipsychotics. Partial or milder forms may be associated with newer anti-\npsychotics, but neuroleptic malignant syndrome varies in severity even\nwith older drugs. Dopamine antagonists used in medical settings (e.g.,\nmetoclopramide, prochlorperazine) have also been implicated. Paren-\nteral administration routes, rapid titration rates, and higher total drug\ndosages have been associated with increased risk; however, neuroleptic\nmalignant syndrome usually occurs within the therapeutic dosage\nrange of antipsychotics.\nDifferential Diagnosis\nNeuroleptic malignant syndrome must be distinguished from other\nserious neurological or medical conditions, including central ner-\nvous system infections, inflammatory or autoimmune conditions,\nstatus epilepticus, subcortical structural lesions, and systemic condi-\ntions (e.g., pheochromocytoma, thyrotoxicosis, tetanus, heat stroke).\nMedication-Induced Movement Disorders 349\nNeuroleptic malignant syndrome also must be distinguished from\nsimilar syndromes resulting from the use of other substances or medi-\ncations, such as serotonin syndrome; parkinsonian hyperthermia syn-\ndrome following abrupt discontinuation of dopamine agonists; alcohol Cases, suggesting underlying vulnerability in some patients; how-\never, genetic findings based on neurotransmitter receptor polymor-\nphisms have not been replicated consistently. nearly all dopamine antagonists have been..."
}